MedTrace Logo

Transmission of Tuberculosis Among Illicit Drug Use Linkages

NCT04151602 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 802

Last updated 2025-04-03

No results posted yet for this study

Summary

Tuberculosis (TB) is the leading infectious disease killer globally and leading cause of death in persons with HIV. The most effective way to reduce TB incidence and mortality is to interrupt transmission. This requires finding and treating individuals with TB disease early, including those with subclinical disease. Molecular epidemiologic studies and mathematical models have shown that the primary approach to case finding-household contact tracing-identifies only 8-19% of transmissions in high TB and TB/HIV burden settings. Thus there is a clear need to identify new groups and settings where TB transmission occurs. Spatial clustering of individuals with higher rates of progression from infection to disease, such as those with HIV and malnourishment, can also form transmission hotspots. Illicit drug (i.e., methamphetamines, crack/cocaine, opiates) users have higher TB infection prevalence and disease incidence compared to non-users, likely due to significant within-group transmission and/or clustered vulnerability. Increased transmission among people who use illicit drugs (PWUD) could result from creation of more efficient TB transmitters, increased close contact among transmitters, increased rates of primary progression from infection to disease among contacts, or a combination. Interrogation of illicit drug user networks for TB transmission, therefore, holds great potential as a target for early case identification and linkage to treatment, with potential benefit for halting transmission to the broader population.

Conditions

Interventions

BEHAVIORAL

Smoked illicit drug use

The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones

Sponsors & Collaborators

  • University of Stellenbosch

    collaborator OTHER

  • Desmond Tutu HIV Foundation

    collaborator OTHER

  • Boston University

    collaborator OTHER

  • Medical Research Council, South Africa

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Boston Medical Center

    lead OTHER

Principal Investigators

  • Karen Jacobson, MD MPH · Boston Medical Center/ BUMC

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-22
Primary Completion
2023-10-26
Completion
2024-08-22

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04151602 on ClinicalTrials.gov